Latest news with #Glenmark
Time of India
4 days ago
- Business
- Time of India
Glenmark's blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation, a clinical stage biotechnology company focused on oncology, has announced promising results for an innovative drug used for the treatment of relapsed or refractory multiple myeloma (RRMM), a rare form of blood cancer that affects plasma cells in bone marrow. Coded ISB 2001, the drug demonstrated an overall response rate (ORR) of 79% in a Phase 1 global study based on finding from patients who were administered a recommended dose. Patients who had exhausted other advanced treatments, such as CAR-T cell therapy and bi-specific antibodies, also showed encouraging results when given the drug. IGI is an alliance between the New York-based scientific research group Ichnos Sciences and Indian drug maker Glenmark. Senior haematologists say that the drug could potentially be an important candidate in the treatment of patients - who exhaust other therapy options due - to its unique mechanism of engaging the body's T cells (that are a vital part of the immune system) along with the attacking two sites on the tumour cell. Dr Shyam Rathi, consultant, clinical hematology, PD Hinduja Hospital & Medical Research Centre in Mumbai, said: 'It can definitely be a game changer in treatment of multiple myeloma which keeps relapsing thus exhausting treatment options quickly. This new drug looks very attractive because it targets two different sites on the cancer cell and it engages the body's own T-cells.' 'We have existing bi-specific antibodies where the target is only one antigen and they develop resistance very fast. However, ISB 2001 targets the two sites on the cancer cell and we expect some better results. It looks exciting in the future.' In lay terms, ISB 2001 binds to three sites on the cancer tumour. First, the ISB 2001 activates the CD-3 T-lymphocytes, which are the cells that have the natural attacking power against tumour cells. Next, it binds to two additional sites. The first is BCMA (a protein found on myeloma cells), which is the target for bi-specific antibodies but there is also CD38, which is the binding site of the widely prescribed drug called daratumumab, branded as Darzalex by Johnson & Johnson. Glenmark, which is pinning a lot of hopes on the new drug, is in advanced talks with multiple global Big Pharma companies for a licensing deal, Chairman and Managing Director Glenn Saldanha told analysts over an earnings call recently. 'The discussions are progressing really well, and we anticipate a positive outcome very quickly,' said Saldhana. He said a deal for ISB 2001 will 'really be transformational for Glenmark' and 'will overshadow anything else that we are doing in the near term.' 'You should see some visibility around a licensing deal pretty quickly.' Last year Ichnos and Glenmark entered into a partnership for discovery of cutting-edge therapies, specifically to treat blood related cancers and malignancies like multiple myeloma. The global market for multiple myeloma treatment is seeing a surge. The business for such drugs is expected to rise to $33 billion by 2030, up from $23.5 billion in 2023,according to Bloomberg Intelligence estimates. Hang Quach, professor of haematology at the University of Melbourne noted that the data presented on ISB 2001 highlighted the 'remarkable anti-myeloma activity of this first-in-class trispecific antibody-T cell engager in heavily pre-treated RRMM patients' including those who have exhausted other approved therapies. According to Quach, ISB 2001 has the potential 'to redefine the treatment landscape for multiple myeloma, offering new hope for patients with limited therapeutic options.' The drug demonstrated a favourable safety profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported.
Economic Times
29-05-2025
- Business
- Economic Times
I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300
ICICI Securities has maintained a Reduce call on Glenmark Pharmaceuticals with a revised target price of Rs 1,300 (earlier Rs 1,265). The current market price of Glenmark is Rs 1383.9. Glenmark Pharmaceuticals, incorporated in 1977, is a Mid Cap company with a market cap of Rs 39083.06 crore. Glenmark Pharma's key products/revenue segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023. ADVERTISEMENT Financials For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 3267.89 crore, down -4.41 % from last quarter Total Income of Rs 3418.68 crore and down -14.81% from last year same quarter Total Income of Rs 3836.12 crore. The company has reported net profit after tax of Rs 4.38 crore in the latest quarter. The company's top management includes Saldanha, Pinto, Mr.V S Mani, Mrs.B E Saldanha, Ramasastry, Iyer, V Desai, Bhattacharjee. Company has Walker, Chandiok & as its auditors. As on 31-03-2025, the company has a total of 28 crore shares outstanding. Investment RationaleThe stock currently trades at valuations of 23.8x FY26E and 19.3x FY27E earnings, and EV/EBITDA multiples of 14.5x FY26E and 11.9x FY27E, respectively. ICICI Securities cuts revenue and EBITDA by ~2% each for FY26/27E to factor in slower growth in India. Enhanced free cash generation and maintaining a prudent balance sheet are essential avenues to be watched out in quarters ahead. Thy expect 10.3%/15.0%/20.8% revenue/ EBITDA/PAT CAGR over FY25-27E, with EBITDA margin at 19.4% in FY27E. I-Sec maintains a REDUCE call with higher target price of Rs 1,300 (earlier Rs 1,265), based on 18x FY27E EPS (22x FY26E EPS previously). Key upside risks: Healthy launches, faster recovery in the US. Promoter/FII Holdings Promoters held 46.65 per cent stake in the company as of 31-Mar-2025, while FIIs owned 23.15 per cent, DIIs 14.6 per cent. (You can now subscribe to our ETMarkets WhatsApp channel) Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.
The Hindu
09-05-2025
- Health
- The Hindu
India's #1 Dermat-Prescribed Company Targets Hair Fall
It's not an illusion – quite a few folks see more hair fall in the summer. Sweltering heat, sun rays, sweat, and pollution fuel the perfect hurricane of scalp strain. If you're already facing thinning, postpartum hair fall, or post-disease hair fall, summer aggravates the situation. (Source: Hsiang EY, Semenov YR, Aguh C, Kwatra SG. Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016. Br J Dermatol 2018;178:978–9). But cheer up: a new science-backed solution, Bontress Pro+ Scalp Serum by Glenmark is getting noticed for helping with visible hair growth, with support from dermatologists and actual test results. The Summer Hair Fall Struggle Is Real In the summer, sweat and sebum production are higher. Paired with dust and UV damage, this can put stress on hair follicles, make roots weaker, and cause more visible shedding. Changes in diet, hydration, and stress levels also occur during the warmer months for many people – all of which can cause seasonal hair fall. (Source: Hsiang EY, Semenov YR, Aguh C, Kwatra SG. Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016. Br J Dermatol 2018;178:978–9). This is where Bontress Pro+ Scalp Serum comes in – a clinically proven solution that's been causing ripples in the trichology world for its noticeable, visible improvements in hair growth. Clinically Proven Results That Speak for Themselves In a recent clinical trial done on 36 healthy men and women suffering from early-stage hair fall, the outcome was nothing less than phenomenal. (Source: Based on clinical study on volunteers who used it consistently for 84 days. Data on file. Individual results may vary. Consult a dermatologist for personalized advice.) 94% of subjects experienced noticeable hair growth in as little as 28 days 68% decrease in hair loss after 12 weeks 100% of users saw new hair growth by week 12 Individual results may differ, but this marks a breakthrough for hair science – literally. The Science Behind the Serum: Driven by 4 Advanced Peptides What makes Bontress Pro+ unique is its powerful combination of four clinically proven peptides, each addressing a distinct cause of hair thinning: 1. Redensyl® – Stimulates stem cells of the scalp to rebuild follicles and increase new hair growth. (Source: RedensylTM. 2. Capixyl™ – Assists in anti-inflammatory benefits and enhancing anchorage of the hair, keeping hair from falling prematurely. (Source: CapixylTM. Folligain. 3. Anagain™ – Increases the anagen phase (growing phase) of the hair cycle so that you keep your hair for a longer duration. (Source: AnaGainTM. Mibelle Biochemistry. 4. Procapil™ – Gives hair follicles strength and limits breakage through enhanced circulation and nutrition of the scalp. (Source: ProcapilTM. FleboIn. Combined, this blend of actives targets the root causes of hair loss—not only the symptoms. Lightweight, Non-Greasy, and Summer-Ready Unlike most tacky oils and oily serums, Bontress Pro+ contains Pro-Lipo Neo™ Technology, which enables 2.4x greater absorption into the scalp. This means it penetrates active ingredients deeper and quicker without leaving any residue (Source: Pro-Lipo™ Neo. LucasMeyer Cosmetics. Its liquid, quick-drying texture makes it perfect for everyday wear, particularly in warm and humid weather. You can apply it, leave it in, and go about your day without fear of buildup or weight. Real Stories, Real Confidence Restored For many customers, Bontress Pro+ is a hair product, but it's also a confidence builder. Sowmya, a teacher, remembers how hair fall made her feel emotionally: 'My hair used to be down to my knees. Then stress and scalp problems made me shed in huge clumps. Nothing helped—until Bontress Pro+. Within a matter of weeks, I noticed baby hairs returning. After four months, I'm finally back to myself again.' Priyanka, an airline career woman, had a similar experience: 'Seeing my hair fall out was devastating. I thought I was balding. But Bontress Pro+ restored my hopes. By the third month, my hair was stronger, thicker, even healthier-looking. It's transformed my attitude towards myself.' Click here to see our journey Why It Works Even Better in Summer Heat and humidity may cause scalp buildup and inflammation of follicles, exacerbating hair loss. Bontress Pro+'s light texture combats seasonal aggressors, providing moisture and nutrition without getting clogged in pores. For best results, dermatologists advise once-daily application for a minimum of 12 weeks or as recommended by their dermatologist. While individual results may vary, most users experience changes within the first month. Consistent application results in healthier, denser, more resilient hair. So, if you're fed up with seeing your hair fall out strand by strand, particularly in the summer months, Bontress Pro+ could be the solution you've been searching for. 'This article is part of the sponsored content programme.'
&w=3840&q=100)
Business Standard
27-04-2025
- Business
- Business Standard
Glenmark's research arm will be self-funded soon, says Glenn Saldanha
Pharma major evaluating opportunities to out-license key cancer asset ISB-2001, deal likely in H1CY25 Premium Sohini Das Mumbai Listen to This Article Pharma major Glenmark's innovation and research arm will soon be self-funded, as the Mumbai-headquartered company is looking to out-license one of its key cancer assets (ISB-2001) within the next few months. The company's Chairman and Managing Director Glenn Saldanha told Business Standard that post the deal, Glenmark would not need to fund its innovation arm Ichnos Glenmark Innovation (IGI) anymore. 'Very clearly we are hoping to conclude something in this year and post that, IGI will be self-funded and adequately funded to support its research and development (R&D) activities going forward,' Saldanha said. He has fought a long battle
India Today
25-04-2025
- Health
- India Today
India bans select cough syrups for children under 4 amid safety concerns
On April 15, 2025, the government of India released an order restricting the manufacture, distribution, and sale of fixed-dose combination (FDC) cough syrups for children under the age of four that contain chlorpheniramine maleate and phenylephrine hydrocholoride. This came after the recommendation from DTAB and the Subject Expert Commmittee, which emphasised the issues relating to the safety and effectiveness of these products in young previously mentioned medicines include popular brands such as Ascoril Flu Drops and some of Alex by Glenmark, T-Minic by Haleon (previously GlaxoSmithKline), and Maxtra by Zuventus Healthcare. These manufacturers are now required to add label and package insert warnings that say: 'Combination of FDC shall not be given to children below four years of age.'Glenmark and Zuventus Healthcare contested the government's notification claiming that it was illegal to apply it retrospectively. On April 24, 2025, the ruling of the Delhi High Court delegated that this ban will be implemented as sequential meaning it will not include stocks that were made before April fifteen as they were exempted. Nonetheless, the court required these companies to inform all medical professionals through formal advisories and public notices in widely circulated newspapers stating that these FDC cough syrups must never be given to children under four years regardless of the the manufacturers were ordered by the court to submit sworn statements regarding the produced and distributed stocks prior to the new guidelines coming into effect so as to maintain compliance and around the nation have raised issues pertaining to the management of remaining stock of the banned cough syrups post the ban. The IPA or the Indian Pharmaceutical Association has consulted the DCGI or the Drugs Controller General of India inquiring whether the remaining supply is meant to be returned or can be sold until there is zero stock left. Moreover, there is a need for clarification on the dispensing of prescriptions meant for toddlers during this period of shifting stakeholders include the manufacturers, pharmacists, and health care service providers, along with other stakeholders. As such, they have also been suggested alongside more time in the adaptation period to ensure the new regulations are seamlessly measures imposed by the government highlight the necessity of safeguarding children's medicines. The restrictions placed on using selected FDC cough syrups in very young children are intended to avoid certain negative outcomes and safeguard the interests of this sensitive age public notices, along with the warnings, are directed towards ensuring that as a professional, one pays more attention to the targeted health care services and therapeutics as they relate to monitoring changes within the processes of these healthcare sectors, it is crucial that the guardians, pharmaceutical practitioners, and the rest involved in the regulation work closely together to protect the young children's wellbeing while being fully responsible for adapting to the new instruction policies.
